Isto Biologics Strengthens its Bone Graft Substitutes Platform with the Acquisition of NovaBoneHOPKINTON, MA / ACCESS Newswire / August 4, 2026 / Isto Biologics ("Isto"), a biologics company dedicated to advancing bone healing, today announced the acquisition of NovaBone Products LLC ("NovaBone"), a developer and manufacturer of synthetic bone graft products, from Halma plc. Supported by Keensight Capital ("Keensight"), one of the leading private equity managers dedicated to pan-European Growth Buyout[1] investments, the acquisition adds a differentiated portfolio of bioactive glass technologies and expands Isto's ability to support surgeons with a broader range of bone graft options.
